Skip to main content

Parsons Corporation Celebrates TraCSS Victory with Space News Icon Award for Civil Space Achievement of the Year

CHANTILLY, Va., Dec. 08, 2025 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE:PSN), the systems integrator for the Office of Space Commerce’s (OSC) Traffic Coordination System for Space (TraCSS) program, is proud to announce that this groundbreaking advancement in space traffic coordination has been recognized with the esteemed 2025 SpaceNews Icon Award for Civil Space Achievement. This prestigious accolade underscores Parsons’ commitment to advancing safe and efficient operations in an increasingly congested orbital environment. “Receiving the SpaceNews Icon Award for Civil Space Achievement is a tremendous honor for Parsons Corporation and our Space Operations Team,” said James Johnson, senior vice president for Parsons Space Solutions Sector. “This recognition reflects the hard work of our talented teams who have been instrumental...

Continue reading

Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial

Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 1 trial in atopic dermatitis and potential expansion into other immune and inflammatory diseases Highlights ITK inhibition novel mechanism of action affecting T cell receptor signaling and T cell differentiation Presented in an oral session at the 67th American Society of Hematology Annual Meeting & Exposition SOUTH SAN FRANCISCO, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced the presentation of final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma today in...

Continue reading

Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS  – Median duration of complete response and overall survival not yet reached in newly diagnosed NPM1-m patients as of data cutoff – – 65% (31/48) ORR in R/R NPM1-m AML, 83% (19/23) ORR in venetoclax-naïve – – 41% (13/32) ORR in R/R KMT2A-r AML, 70% (7/10) ORR in venetoclax-naïve – – Triplet combination was well tolerated in both newly diagnosed and relapsed/refractory settings; addition of ziftomenib did not increase toxicity beyond that expected with venetoclax/azacitidine alone – – Ziftomenib’s broad clinical development program spans multiple front-line and relapsed/refractory regimens across NPM1-m, FLT3-m and KMT2A-r AML subtypes – – Company-sponsored registrational trials of ziftomenib...

Continue reading

Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting

CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31% CR/CRh rate observed at the highest target dose tested to date; initial dose escalation results in 45 patients demonstrate a favorable safety profile across all doses assessed CLN-049 recently granted Fast Track designation by the U.S. FDA Company to host in-person event on Monday, December 8, at 8:00 p.m. ET CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today shared updated clinical data from its Phase 1 study of CLN-049, a novel, investigational...

Continue reading

Changes in Hiab Leadership Team

HIAB CORPORATION, STOCK EXCHANGE RELEASE, 8 DECEMBER 2025 AT 5:00 PM (EET) Changes in Hiab Leadership Team Sanna Ahonen, EVP, Strategy and Sustainability and member of Hiab Leadership team, has decided to step down from her role. Effective immediately, her responsibilities transition to Kimberly Allan, EVP, Business Excellence. To facilitate a structured handover, Sanna will remain available upon request until 4 June 2026. “On behalf of the entire leadership team, I want to sincerely thank Sanna for her contributions to Hiab. She has played an important role in our demerger and leading our strategy and sustainability teams. I wish her every success in her future endeavours,” says Hiab’s President and CEO Scott Phillips. For further information, please contact:Birgitte Skade, Executive Vice President, Marketing and Communications,...

Continue reading

UPDATE — Prospect Enhanced Yield Fund Announces 9.0% Annualized Total Cash Distribution Rate (on Net Asset Value) for October 2025 through December 2025

NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) — Prospect Enhanced Yield Fund (“PENF” or the “Fund”) announced today that the Fund’s Board of Directors has declared monthly cash shareholder distributions for October 2025, November 2025, and December 2025. These distributions represent the first, second, and third monthly distributions paid by the Fund. The annualized total cash distribution is $2.28 per share (9.0% annualized rate based on the October 20, 2025 net asset value), for distributions with record dates between October 30, 2025 and December 30, 2025 based on the current net asset value of $25.29 per common share.  The cash distribution will have monthly record dates and will be payable monthly to common stockholders of record at the close of business each month. These declared distributions equal $0.57 on a quarterly basis...

Continue reading

Gold Royalty Announces Upsizing of Previously Announced Bought Deal Financing

BASE SHELF PROSPECTUS AND PRELIMINARY PROSPECTUS SUPPLEMENT ACCESSIBLE AND FINAL PROSPECTUS SUPPLEMENT TO BE ACCESSIBLE WITHIN TWO BUSINESS DAYS ON SEDAR+ VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) — Gold Royalty Corp. (“Gold Royalty” or the “Company”) (NYSE American: GROY) is pleased to announce that as a result of excess demand, it has agreed with National Bank Capital Markets, BMO Capital Markets, and RBC Capital Markets as joint bookrunners, on behalf of a syndicate of underwriters (collectively, the “Underwriters”) to increase the size of its previously announced bought deal financing. Gold Royalty will now issue 22,500,000 common shares of the Company (the “Common Shares”) at a price of US$4.00 per Common Share (the “Offering Price”) for aggregate gross proceeds of US$90.0 million (the “Offering”). The Company...

Continue reading

Miata Metals Announces Closing of $11.5 Million Public Offering Including Full Exercise of the Over-Allotment Option

Not for distribution to United States newswire services or for dissemination in the United States VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) — Miata Metals Corp. (CSE:MMET) (FSE: 8NQ) (OTCQB: MMETF) (“Miata” or the “Company”) is pleased to announce that it has closed its previously announced short form prospectus offering (the “Offering”) of common shares of the Company (“Common Shares”). The Company issued a total of 23,958,500 Common Shares at a price of $0.48 per share for gross proceeds of $11,500,080, inclusive of the full exercise of the over-allotment option. The Common Shares were offered by way of a short form prospectus dated December 3, 2025 (the “Prospectus”) filed with the securities regulatory authorities in each of the provinces of Canada, other then the province of Québec, and in such other jurisdictions...

Continue reading

Jiuzi Holdings Inc. Announce Reverse Split Record Date

HANGZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) — Jiuzi Holdings Inc. (NASDAQ: JZXN; the “Company” or “JZXN”),  a leading new energy vehicle (NEV) dealership group operating under the brand name “Jiuzi” in China is reporting that its board of directors has approved a reverse stock split (the “Reverse Stock Split”) of the Company’s ordinary shares, a par value of US$0.00195 each (the “Ordinary Shares”), at a ratio of 1-for-40, with a post-Reverse Stock Split par value of US$0.078. The Company is undertaking the Reverse Stock Split with the objective of meeting the minimum $1.00 per Ordinary Share bid requirement for maintaining the listing of the Ordinary Shares on The Nasdaq Capital Market. The Reverse Stock Split will be effective at 04:01 p.m. (ET) on Wednesday, December 10, 2025 (the “Record Date”) and the Ordinary Shares will...

Continue reading

Schouw & Co. share buy-back programme, week 49 2025

On 5 May 2025, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 20 of 2 May 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 120 million during the period 5 May to 31 December 2025. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).Trading day No. of shares Average price Amount    Accumulated until 28 November 2025 196,200 597.51 117,231,745    Monday, 1 December 2025 600 609.41 365,646    Tuesday, 2 December 2025 400 614.38 245,752    Wednesday, 3 December 2025 400 623.50 249,400    Thursday, 4 December 2025 400 621.84 248,736    Friday,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.